FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study EDITORIAL COMMENTS

被引：0
|
作者：
de Reijke, Theo M. [1 ]
机构：
[1] Acad Med Ctr, Dept Urol, Amsterdam, Netherlands
来源：
JOURNAL OF UROLOGY | 2017年 / 197卷 / 06期
关键词：
D O I：
10.1016/j.juro.2016.12.132
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1417 / 1417
页数：1
相关论文
共 9 条
  • [1] FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study
    Beukers, Willemien
    van der Keur, Kirstin A.
    Kandimalla, Raju
    Vergouwe, Yvonne
    Steyerberg, Ewout W.
    Boormans, Joost L.
    Jensen, Jorgen B.
    Lorente, Jose A.
    Real, Francisco X.
    Segersten, Ulrike
    Orntoft, Torben F.
    Malats, Nuria
    Malmstrom, Per-Uno
    Dyrskjot, Lars
    Zwarthoff, Ellen C.
    JOURNAL OF UROLOGY, 2017, 197 (06): : 1410 - 1417
  • [2] FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study REPLY
    不详
    JOURNAL OF UROLOGY, 2017, 197 (06): : 1418 - 1418
  • [3] The Diagnostic and Prognostic Performance of Urinary FGFR3 Mutation Analysis in Bladder Cancer Surveillance: A Prospective Multicenter Study
    van Kessel, Kim E.
    Zwarthoff, Ellen C.
    UROLOGY, 2015, 86 (06) : 1190 - 1191
  • [4] TERT Promoter Mutations and TERT mRNA but Not FGFR3 Mutations Are Urinary Biomarkers in Han Chinese Patients With Urothelial Bladder Cancer
    Wang, Kun
    Liu, Tiantian
    Liu, Cheng
    Meng, Yan
    Yuan, Xiaotian
    Liu, Li
    Ge, Nan
    Liu, Jikai
    Wang, Chang
    Ren, Hongbo
    Yan, Keqiang
    Hu, Sanyuan
    Xu, Zhonghua
    Fan, Yidong
    Xu, Dawei
    ONCOLOGIST, 2015, 20 (03): : 263 - 269
  • [5] Clinical Validation and Performance Assessment of a TERT/FGFR3/KRAS Mutation screening urinary biomarker test for recurrence surveillance in non-muscle invasive bladder cancer
    Ramos, P.
    Bras, J. P.
    Dias, C.
    Bessa-Goncalves, M.
    Botelho, F.
    Silva, J.
    Matins-Silva, C.
    Pacheco-Figueiredo, L.
    EUROPEAN UROLOGY, 2024, 85 : S1174 - S1175
  • [6] THE PROGNOSTIC VALUE OF FGFR3 MUTATIONAL STATUS FOR DISEASE RECURRENCE AND PROGRESSION DEPENDS ON ALLELIC LOSSES AT 9P22: A PROSPECTIVE AND PRELIMINARY STUDY IN 58 NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS
    Ploussard, G.
    Soliman, H.
    Dubosq, F.
    Verine, J.
    Desgrandchamps, F.
    De The, H.
    Mongiat-Artus, P.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 79 - 79
  • [7] Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer
    Roperch, Jean-Pierre
    Grandchamp, Bernard
    Desgrandchamps, Francois
    Mongiat-Artus, Pierre
    Ravery, Vincent
    Ouzaid, Idir
    Roupret, Morgan
    Phe, Veronique
    Ciofu, Calin
    Tubach, Florence
    Cussenot, Olivier
    Incitti, Roberto
    BMC CANCER, 2016, 16
  • [8] Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer
    Jean-Pierre Roperch
    Bernard Grandchamp
    François Desgrandchamps
    Pierre Mongiat-Artus
    Vincent Ravery
    Idir Ouzaid
    Morgan Roupret
    Véronique Phe
    Calin Ciofu
    Florence Tubach
    Olivier Cussenot
    Roberto Incitti
    BMC Cancer, 16
  • [9] Bacillus Calmette-Guerin Is Superior to a Combination of Epirubicin and Interferon-α2b in the Intravesical Treatment of Patients with Stage T1 Urinary Bladder Cancer. A Prospective, Randomized, Nordic Study
    Duchek, Milos
    Johansson, Robert
    Jahnson, Staffan
    Mestad, Oddvar
    Hellstrom, Pekka
    Hellsten, Sverker
    Malmstrom, Per-Uno
    EUROPEAN UROLOGY, 2010, 57 (01) : 25 - 31
1